Moderna (MRNA) Reports Q3 EPS Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
November 6, 2019 7:00 AM ESTPositive interim results announced from Phase 1 CMV vaccine (mRNA-1647) study
Positive interim results announced from Phase 1 mRNA encoding chikungunya antibody (mRNA-1944) study
First participant dosed in Phase 1b age de-escalation study of hMPV+PIV3 vaccine (mRNA-1653)
Cash, cash equivalents and investments at the end of the quarter were $1.34 billion, and are expected to be approximately $1.20 billion at the end of 2019
Net cash used in operating activities and purchases of property and equipment is expected to total approximately $500 million in 2019, and between... More
